Clinical Trials Browser

Phase 3 × Esophageal Neoplasms × Irinotecan × Clear all

NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Phase 3 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT03933449 2023-03-29

KEYNOTE-181

Phase 3 Completed

123 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

Phase 3 Completed

628 enrolled 27 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02319187 2015-08-03

Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial

Phase 3 Unknown

Gastrointestinal

Esophageal Neoplasms